The maraviroc expanded access program - safety and efficacy data from an open-label study [0.03%]
柯立抗扩大适用计划——一项开放标记试验的安全性和有效性数据
Adriano Lazzarin,Jacques Reynes,Jean-Michel Molina et al.
Adriano Lazzarin et al.
Purpose: The maraviroc (MVC) expanded access program (EAP) was initiated to increase MVC availability to patients with limited treatment options. Darunavir (DRV), raltegravir (RAL), and etravirine (ETV) were either recent...
Multicenter Study
HIV clinical trials. 2015 Jan-Feb;16(1):10-21. DOI:10.1179/1528433614Z.0000000002 2015
Reliability and validity of a single-item rating scale to monitor medication adherence for people living with HIV and lower health literacy [0.03%]
单一评分量表监测HIV患者药物依从性的可靠性和有效性（低健康素养人群）
Jennifer A Pellowski,Seth C Kalichman,David J Finitsis
Jennifer A Pellowski
Background: Monitoring medication adherence in clinical and research settings may be especially challenging for people with lower literacy skills. Objecti...
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment [0.03%]
恩夫韦肽在轻中度肾功能不全的HIV感染者中的应用
Cheryl K McDonald,Claudia Martorell,Moti Ramgopal et al.
Cheryl K McDonald et al.
Background: Cobicistat (COBI) is a pharmacoenhancer that optimizes systemic exposures of protease inhibitors (PIs) such as atazanavir (ATV) and darunavir (DRV). ...
Clinical Trial
HIV clinical trials. 2014 Nov-Dec;15(6):269-73. DOI:10.1310/hct1506-269 2014
Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis [0.03%]
恩曲他滨富马酸替诺福韦二吡呋酯治疗HIV感染者：一项 Meta 分析研究
Sheng-Li Li,Peng Xu,Lei Zhang et al.
Sheng-Li Li et al.
Objective: The aim of this study was to determine the effectiveness and safety of rilpivirine in treatment-naive adults infected with HIV-1. Methods: ...
Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175) [0.03%]
在多样性的多国背景下开始HIV-1治疗方案后的肾脏和代谢毒性：ACTG PEARLS（A5175）试验中的重点关注安全性分析
F Touzard Romo,L M Smeaton,T B Campbell et al.
F Touzard Romo et al.
Background: Convenient dosing, potency, and low toxicity support use of tenofovir disoproxil fumarate (TDF) as preferred nucleotide reverse transcriptase inhibitor (NRTI) for HIV-1 treatment. However, renal and metabolic ...
Randomized Controlled Trial
HIV clinical trials. 2014 Nov-Dec;15(6):246-60. DOI:10.1310/hct1506-246 2014
Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies [0.03%]
以肾不良反应为假定原因导致新型HIV-1患者停用富马酸替诺福韦二吡呋酯片：随机临床试验的meta分析研究
Jonathan Winston,Michel Chonchol,Joel Gallant et al.
Jonathan Winston et al.
Background: Safety and efficacy of tenofovir disoproxil fumarate (TDF) as a component of antiretroviral therapy (ART) have been demonstrated in clinical trials. TDF nephrotoxicity has been reported in both HIV-infected an...
Meta-Analysis
HIV clinical trials. 2014 Nov-Dec;15(6):231-45. DOI:10.1310/hct1506-231 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients [0.03%]
埃维拉格酶抑制剂/哥比西拉特/恩曲他滨/替诺福韦DF与阿塔南维尔+利托那维尔+恩曲他滨/替诺福韦DF在抗逆转录病毒药物初治患者中的144周耐药分析
Rima Kulkarni,Michael E Abram,Damian J McColl et al.
Rima Kulkarni et al.
Objective: To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-...
Clinical Trial
HIV clinical trials. 2014 Sep-Oct;15(5):218-30. DOI:10.1310/hct1505-218 2014
Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial [0.03%]
拉西夫定与埃特格韦治疗非核苷类反转录酶抑制剂耐药的HIV-1感染患者的疗效和安全性：2b期随机临床试验
Edwin DeJesus,Gerd Fätkenheuer,Catherine Orrell et al.
Edwin DeJesus et al.
Objective: To assess the efficacy and safety of lersivirine versus etravirine in patients with HIV-1 and prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance. ...
Clinical Trial
HIV clinical trials. 2014 Sep-Oct;15(5):209-17. DOI:10.1310/hct1505-209 2014
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients [0.03%]
多替拉韦：整合酶抑制剂初治患者临床与实验室安全性分析
L Curtis,G Nichols,C Stainsby et al.
L Curtis et al.
Background: The efficacy of dolutegravir (DTG) has been demonstrated in 5 randomized studies in integrase inhibitor (INI)-naive adult populations. To date, a detailed safety review of DTG has not been provided in the lite...
The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials [0.03%]
2013年WHO抗逆转录病毒治疗指南对HIV人群预防试验的影响
Eric Ross,Frank Tanser,Pamela Pei et al.
Eric Ross et al.
Background: Several cluster-randomized HIV prevention trials aim to demonstrate the population-level preventive impact of antiretroviral therapy (ART). 2013 World Health Organization (WHO) guidelines raising the ART initi...